Freeline Therapeutics Holdings plc

0.7484+0.0285+3.96%Vol 41.75K1Y Perf -77.64%
Oct 5th, 2022 16:00 DELAYED
BID0.7000 ASK0.7671
Open0.7299 Previous Close0.7199
Pre-Market0.78 After-Market-
 0.03 4.22%  - -
Target Price
9.00 
Analyst Rating
Strong Buy 1.40
Potential %
1.10K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
3.40 
Earnings Rating
Market Cap48.63M 
Earnings Date
8th Nov 2022
Alpha-0.11 Standard Deviation0.15
Beta-0.22 

Today's Price Range

0.70100.00

52W Range

0.65003.54

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
10.09%
1 Month
-11.95%
3 Months
-22.72%
6 Months
-29.40%
1 Year
-77.64%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FRLN0.74840.02853.96
AAPL146.400.30000.21
GOOG102.22-0.1900-0.19
MSFT249.200.32000.13
XOM99.123.85004.04
WFC43.31-0.2300-0.53
JNJ165.11-0.5100-0.31
FB196.640.99000.51
GE67.44-0.1000-0.15
JPM110.39-1.3800-1.23
 
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.54-0.3240.74
Q01 2022-0.58-0.63-8.62
Q04 2021-0.72-0.97-34.72
Q03 2021-0.99-0.8613.13
Q02 2021-0.96-1.12-16.67
Q01 2021-0.78-0.98-25.64
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date8th Nov 2022
Estimated EPS Next Report-0.43
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume41.75K
Shares Outstanding64.97K
Shares Float64.73M
Trades Count257
Dollar Volume30.57K
Avg. Volume41.05K
Avg. Weekly Volume18.40K
Avg. Monthly Volume27.91K
Avg. Quarterly Volume76.85K

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) stock closed at 0.7484 per share at the end of the most recent trading day (a 3.96% change compared to the prior day closing price) with a volume of 41.75K shares and market capitalization of 48.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 236 people. Freeline Therapeutics Holdings plc CEO is Theresa Heggie.

The one-year performance of Freeline Therapeutics Holdings plc stock is -77.64%, while year-to-date (YTD) performance is -62.2%. FRLN stock has a five-year performance of %. Its 52-week range is between 0.65 and 3.54, which gives FRLN stock a 52-week price range ratio of 3.40%

Freeline Therapeutics Holdings plc currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.49, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -68.66%, a ROC of -59.83% and a ROE of -92.02%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Freeline Therapeutics Holdings plc, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.43 for the next earnings report. Freeline Therapeutics Holdings plc’s next earnings report date is 08th Nov 2022.

The consensus rating of Wall Street analysts for Freeline Therapeutics Holdings plc is Strong Buy (1.4), with a target price of $9, which is +1 102.57% compared to the current price. The earnings rating for Freeline Therapeutics Holdings plc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Freeline Therapeutics Holdings plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Freeline Therapeutics Holdings plc has a Sell technical analysis rating based on Technical Indicators (ADX : 43.46, ATR14 : 0.07, CCI20 : -44.16, Chaikin Money Flow : -0.19, MACD : -0.04, Money Flow Index : 45.83, ROC : -10.19, RSI : 51.40, STOCH (14,3) : 41.17, STOCH RSI : 1.00, UO : 46.81, Williams %R : -58.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Freeline Therapeutics Holdings plc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
4 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (20.00 %)
1 (20.00 %)
1 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.40
Strong Buy
1.40

Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings PLC is a clinical stage, systemic AAV-based gene therapy company. The company is developing therapies for Haemophilia B, Fabry disease, Gaucher disease, and other diseases.

CEO: Theresa Heggie

Telephone: +44 1438906870

Address: Gunnels Wood Road, Stevenage SG1 2FX, Hertfordshire, GB

Number of employees: 236

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

53%47%

Bearish Bullish

53%47%

Bearish Bullish

60%40%


News

Stocktwits